57 results on '"Amin, Mahul B."'
Search Results
2. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
3. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting
4. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors
5. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
6. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
7. Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis.
8. Flat intraurothelial lesions of the urinary bladder-do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice.
9. Corrigendum to “Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes” [European Urology Oncology (2023)]
10. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.
11. Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes.
12. Reply to Yongbao Wei, Haijian Huang, and Liefu Ye’s Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469–82.
13. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
14. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
15. Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile.
16. A tribute to Prof. Ondrej Hes, MD, PhD (1968-2022).
17. Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study.
18. Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer.
19. Correction to: Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes.
20. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
21. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
22. A Contemporary Update on Pathology Standards for Bladder Cancer: Transurethral Resection and Radical Cystectomy Specimens
23. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
24. ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology
25. A Contemporary Update on Pathology Reporting for Prostate Cancer: Biopsy and Radical Prostatectomy Specimens
26. Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney.
27. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization.
28. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume.
29. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications.
30. Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma.
31. Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47 909 cases using the National Cancer Data Base.
32. Osteoclast-rich undifferentiated carcinomas of the urinary tract.
33. Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors.
34. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
35. Urothelial (Transitional Cell) Papilloma of the Urinary Bladder: A Clinicopathologic Study of 26 Cases.
36. Concurrent Angiomyolipoma and Renal Cell Neoplasia: A Study of 36 Cases.
37. Relationship of Cytokeratin 20 and CD44 Protein Expression with WHO/ISUP Grade in pTa and pT1 Papillary Urothelial Neoplasia.
38. Intrarenal Schwannoma: A Report of Four Cases Including Three Cellular Variants.
39. Thyroid Transcription Factor-1 Is Expressed in Extrapulmonary Small Cell Carcinomas but Not in Other Extrapulmonary Neuroendocrine Tumors.
40. Correction to: Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia.
41. Cancer-Specific Loss of ß-Defensin 1 in Renal and Prostatic Carcinomas.
42. Reply to Vincenzo Di Nunno, Matteo Santoni, Alessia Cimadamore, Nicola Battelli, and Francesco Massari's Letter to the Editor re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, et al. Updates in the Eight Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560–9.
43. Method for Procuring Specific Populations of Viable Human Prostate Cells for Research.
44. The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521.
45. Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).
46. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
47. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.
48. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
49. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.
50. Machine learning approaches to analyze histological images of tissues from radical prostatectomies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.